Pfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Pfizer Inc. (NYSE: PFE) has disclosed promising findings from a Phase 3 clinical trial investigating the efficacy of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in conjunction with lenalidomide and rituximab…

Read MorePfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Hansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates

Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovative pharmaceutical company in China, and Biotheus Inc. (Biotheus), a clinical-stage biotech company specializing in biologics for oncology and inflammatory…

Read MoreHansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates

Update Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls

In Lisbon, Portugal, the World Health Organization (WHO) recently hosted an expert panel to reassess the Toxic Equivalency Factors (TEFs) for chlorinated dioxin-like compounds, initially established in 2005. Background: Since…

Read MoreUpdate Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls